Summary
The new bioresorbable drug-eluting stents are deliverable, usable at bifurcations, compatible with short-term dual antiplatelet therapy, and low cost. Long-term outcomes are needed, however, to confirm their safety and efficacy compared with permanent drug-eluting stents.
- coronary artery disease
- stent
- drug-eluting stents
- bare metal stents
- target lesion revascularization
- stent thrombosis
- cardiology & cardiovascular medicine clinical trials
- percutaneous coronary intervention
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.